
To cure a larger fraction of patients with high risk disease we will need a truly integrated approach. I am surpised that there was not more salvage RT in PROTEUS.
✓Urologic oncologist & surgeon; Chairman, Department of Urology, Pediatric Urology and Urooncology, University Hospital Essen

To cure a larger fraction of patients with high risk disease we will need a truly integrated approach. I am surpised that there was not more salvage RT in PROTEUS.

It adds data to the discussion. The RP only substudy comes next year. SPCG15 will be very important. Primary PET staging not available in PROTEUS. Comparison to ENZARAD and ATLAS will be interesting… I am very happy that PROTEUS is positive.

Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… Honored to be involved - lots to discuss and lots to come

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study thelancet.com/journals/lanon… In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer Developed and validated across 35 global sites, ✅ Models demonstrated strong discrimination (C-index ~0.83–0.84). ✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design. @CalaisJeremie @DrMHofman @thomashopemd @drlouiseemmett @DrAGafita @ProfKHerrmann @ProfHadaschik @Dr_K_Rahbar @bjartell @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists #EAU26

back on X for scientific reasons because the alternative platforms unfortunately did not fulfill my expectations

I am leaving X with a sad eye moving on to more reasonable platforms.

PEACE-1 RT is now published online at @TheLancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: thelancet.com/journals/lance…

Happy to share: Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer - ScienceDirect sciencedirect.com/science/ar…

We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann @stefanofanti4

Delighted to share our latest on #18F_PSMA_PET just published in cool new @JUOpenPlus! •n=1335 scans from 1220 men •1°: PSMA 96% vs MRI 89% sens. for pros lesions at RP •2°: PSA 0.2-0.49 post RP/RT ➡️ avidity in 57.8% BUT high false +ves (esp ribs) journals.lww.com/juop/fullte…

Sharing key takeaways from my #ASTRO2024 presentation! I'm grateful for the support I've received—thank you, @ASTRO, @MGHCancerCenter @theNCI & @Pcfnews. It’s a win for our field that both #ProtonTherapy & #IMRT are equally highly effective for localized #ProstateCancer.

🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! nature.com/articles/s41586-0…

Our latest paper on risk stratified prostate cancer testing - TARGET study, a simultaneous evaluation of PRS, PSAd, F/T PSA, phi in a PSA triggered MRI diagnostic pathway + testing different defn of ‘clinical significance’ link.springer.com/10.1186/s1…

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN

Outstanding presentation by @drjefstathiou #ASTRO24 showing no improvement in any outcome with proton therapy for localised prostate cancer compared to photon therapy. Congratulations to all authors! 👏

the study did not show a meaningful difference. DFS was improved in pts with higher risk of recurrence, such as sRCC, PDL1+ or T4. Getting patient populations right is of clinical interest and leads to stronger recommendations in these groups of patients in my daily practice